Blogs about: Assay Directed Therapy

Featured Blog

HER2 Two

I met a charming patient in my office this week. A gentleman with advanced gastric cancer. Upon further examination of his cancer, the adenocarcinoma cells were found to be strongly positive for human… more →

Dr. Robert A. Nagourney - Rational Therapeutics - Blog

HER2 Two — 4 comments

Dr. Robert A. Nagourney wrote 2 months ago: I met a charming patient in my office this week. A gentleman with advanced gastric cancer. Upon furt … more →

Tags: Dr. Robert A. Nagourney, Outliving Cancer, Chemosensitivity-resistance Testing, Dr. Robert Nagourney, Gastric Cancer, HER2, trastuzumab

Cancer and the Great Divide — 4 comments

Dr. Robert A. Nagourney wrote 5 months ago: There are two types of cancer patients: those we can treat and those we can’t. As I reflect on this … more →

Tags: Cancer drug development, EVA-PCD™, Cancer, Chemotherapy drug development, Dr. Robert Nagourney, EVA-PCD, functional profiling

Phar Lap and the Treatment of Leukemia — 1 comment

Dr. Robert A. Nagourney wrote 5 months ago: Phar Lap (1926-1932) was a thoroughbred horse bred in New Zealand. After winning the Melbourne Cup a … more →

Tags: Dr. Robert A. Nagourney, cancer, Leukemia, Dr. Robert Nagourney, Cancer, Leukemia, assay-directed therapies, trac, E Matutes

Systems Biology Comes of Age: Metastatic Lung Cancer in the Crosshairs

Dr. Robert A. Nagourney wrote 7 months ago: Cancer therapists have long sought mechanisms to match patients to available therapies. Current fash … more →

Tags: programmed cell death, EVA-PCD™, cancer, Cancer Biology, Lung Cancer, cancer and genetics, Systems Biology, genotype and phenotype, lung cancer

Cancer Treatment - A Husband’s View — 1 comment

Dr. Robert A. Nagourney wrote 9 months ago: Guest blogger – Gary Brutsch Dr. Nagourney is currently attending an international conference where … more →

Tags: cancer types, EVA-PCD™, Guest Bloggers, assay-directed therapies, Chemotherapy, Dr. Robert Nagourney, EVA-PCD, Gary Brustch, maintenance therapy

Scientifically-based Functional Profile Under Fire — 2 comments

Dr. Robert A. Nagourney wrote 9 months ago: Winston Churchill once said, “Democracy is the worst form of government, except for all the others t … more →

Tags: Chemosensitivity-resistance Testing, functional profiling, cancer treatment protocols, cancer testing, Dr. Robert Nagourney, Cancer, Cancer Treatment, assay-directed protocols

Chemosensitivity Testing – What It Is and What It Isn’t — 12 comments

Dr. Robert A. Nagourney wrote 1 year ago: Several weeks ago I was consulted by a young man regarding the management of his heavily pre-treated … more →

Tags: Chemosensitivity-resistance Testing, Cancer Biology, Personalized Cancer Treatment, chemotherapy, Colorectal Cancer, Patient Advocacy, microspheroids, Chemotherapy, signal transduction inhibitors

The Death of Christopher Hitchens — 4 comments

Dr. Robert A. Nagourney wrote 1 year ago: Among the more colorful writers, orators and pundits in the later part of the 20th Century and the e … more →

Tags: EVA-PCD™, Dr. Robert A. Nagourney, cancer, functional profiling, Dr. Robert Nagourney, Cancer, EVA-PCD, Cancer Treatment, Christopher Hitchens

Paradigm Shifts

Dr. Robert A. Nagourney wrote 1 year ago: Scientific dogma in all disciplines is slow to change. I am again reminded of this by the recent pub … more →

Tags: Cancer Biology, cancer research, Scientific Dogma, Cancer Research, Copernicus, Dava Sobel, assay-sensitive drugs, assay-resistant drugs, A more perfect heaven

English Patients Denied Access to Ipilimumab — 3 comments

Dr. Robert A. Nagourney wrote 1 year ago: Among the more interesting discoveries in recent years have been two breakthroughs in the management … more →

Tags: functional profiling, Melanoma, cost of cancer, Avastin, Melanoma, Nice, ipilimumab, Yervoy, venurafenib

Faster than the Speed of Light — 3 comments

Dr. Robert A. Nagourney wrote 1 year ago: Last week, scientists at CERN, the European particle physics laboratory located outside Geneva, Swit … more →

Tags: Breast Cancer, Leukemia, Lung Cancer, Melanoma, ovarian cancer, targeted therapies, lung cancer, Leukemia, breast cancer

Is Rationed or Rational Medical Care In Our Future? — 2 comments

Dr. Robert A. Nagourney wrote 1 year ago: We are witness to a sea change in medicine. Doctors and nurses are being replaced by “healthcare pro … more →

Tags: cancer, Evidence based Medicine, cost of cancer, Standardized Cancer Care, targeted therapies, ovarian cancer, lung cancer, Dr. Robert Nagourney, Leukemia

Targeted Therapies for Cancer Confronts Hurdles — 5 comments

Dr. Robert A. Nagourney wrote 1 year ago: The September 1 issue of the ASCO Post, a periodical published by the American Society of Clinical O … more →

Tags: Chemosensitivity-resistance Testing, Dr. Robert A. Nagourney, Targeted Agents, Cancer Biology, Dr. Robert Nagourney, targeted cancer therapies, MD, ASCO Post, Margo J. Fromer

The False Economy of Genomic Analyses — 6 comments

Dr. Robert A. Nagourney wrote 1 year ago: We are witness to a revolution in cancer therapeutics. Targeted therapies, named for their capacity … more →

Tags: Cancer Genomics Testing, cost of cancer, EVA-PCD™, Lung Cancer, Targeted Agents, ALK gene rearrangement, Asco, Chemotherapy, crizotinib

Ovarian Cancer National Alliance 2011 — 3 comments

Dr. Robert A. Nagourney wrote 1 year ago: The July meeting of the OCNA included a lecture by John Hays, MD, from the National Cancer Institute … more →

Tags: Chemosensitivity-resistance Testing, Dr. Robert A. Nagourney, cancer, National Cancer Institute, chemotherapy, Evidence based Medicine, Molecular Signaling, ATP assay, EDR Technology

Lots of Heat No Light – ASCO Technology Assessment Update 2011 — 12 comments

Dr. Robert A. Nagourney wrote 1 year ago: “Once more unto the breach, dear friends.” This famous line from Shakespeare’s Henry V, describes th … more →

Tags: Chemosensitivity-resistance Testing, Cancer Genomics Testing, EVA-PCD™, Dr. Robert A. Nagourney, cancer, ASCO 2011, Chemo resistance, Melanoma, ASCO Technoogy Assessment 2011

Microspheroids - Cancer Cell Clusters and the Assay

hphblog1 wrote 1 year ago: The chemosensitivity-resistance assay (CSRA) is developed on the knowledge that cancer cells do not … more →

Tags: Cancer Testing, Rational Therapeutics, Chemosensitivity-resistance assay, Assay, programmed cell death, assay-directed testing, tumor samples for testing, EVA-PCD, Ex-vivo Analysis

When Surgery Failed, Assay-Directed Therapy Succeeded

hphblog1 wrote 2 years ago: When surgery was no longer an option for a 54-year-old pancreatic cancer patient, he didn’t simply g … more →

Tags: Cancer Testing, Rational Therapeutics, Assay, Dr. Robert Nagourney, pancreatic cancer, pancreatic cancer treatments


Related Tags
All →

Follow this tag via RSS